Literature DB >> 9741457

Adult and neonatal anti-Gal response in knock-out mice for alpha1,3galactosyltransferase.

D C LaTemple1, U Galili.   

Abstract

The knockout mouse to alpha1,3galactosyltransferase (alpha1,3GT KO) lacks the ability to synthesize alpha-gal epitopes (Galalpha1,3Galbeta1,4GlcNAc-R) and is capable of producing low amounts of the natural anti-Gal antibody. The present study indicates that repeated immunization of these mice with rabbit red blood cell (RRBC) membranes results in production of anti-Gal in titers and specificity similar to those in humans. In contrast, immunized wild-type mice completely lack anti-Gal. Anti-Gal in the alpha1,3GT KO mice is produced in the circulation as the various IgG subclasses and as IgM isotype, but not IgA. In view of previous reports on the possible induction of T cell tolerance by immunization of mice with large amounts of antigen up to 24 days of age, we assayed possible induction of neonatal B cell tolerance toward the alpha-gal epitope. Eight-day-old neonates were subjected to immunization with 1 x 10(8) RRBC membranes, or 30 x 10(6) wild type mouse splenocytes, both of which express an abundance of alpha-gal epitopes. These neonatal exposures to alpha-gal epitopes did not prevent subsequent production of anti-Gal. Thus, the tolerance induction to this carbohydrate epitope is likely to be mediated by mechanisms other than those inducing neonatal T cell tolerance.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9741457     DOI: 10.1111/j.1399-3089.1998.tb00027.x

Source DB:  PubMed          Journal:  Xenotransplantation        ISSN: 0908-665X            Impact factor:   3.907


  22 in total

Review 1.  Xenotransplantation: where are we today?

Authors:  M D Dooldeniya; A N Warrens
Journal:  J R Soc Med       Date:  2003-03       Impact factor: 5.344

Review 2.  Use of mouse models to study the mechanisms and consequences of RBC clearance.

Authors:  E A Hod; S A Arinsburg; R O Francis; J E Hendrickson; J C Zimring; S L Spitalnik
Journal:  Vox Sang       Date:  2010-03-21       Impact factor: 2.144

3.  Xeno's paradox: why pig cells are better for tissue transplants than human cells.

Authors:  Philip Hunter
Journal:  EMBO Rep       Date:  2009-06       Impact factor: 8.807

Review 4.  Lessons learned from mouse models of hemolytic transfusion reactions.

Authors:  Eldad A Hod; James C Zimring; Steven L Spitalnik
Journal:  Curr Opin Hematol       Date:  2008-11       Impact factor: 3.284

5.  Removal of anti-Galalpha1,3Gal xenoantibodies with an injectable polymer.

Authors:  Andreas G Katopodis; Richard G Warner; Rudolf O Duthaler; Markus B Streiff; Armin Bruelisauer; Olivier Kretz; Birgit Dorobek; Elke Persohn; Hendrik Andres; Alain Schweitzer; Gebhard Thoma; Willy Kinzy; Valerie F J Quesniaux; Emanuele Cozzi; Hugh F S Davies; Rafael Mañez; David White
Journal:  J Clin Invest       Date:  2002-12       Impact factor: 14.808

6.  Increased immunogenicity of human immunodeficiency virus gp120 engineered to express Galalpha1-3Galbeta1-4GlcNAc-R epitopes.

Authors:  Ussama Abdel-Motal; Shixia Wang; Shan Lu; Kim Wigglesworth; Uri Galili
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

Review 7.  α-Gal Nanoparticles in Wound and Burn Healing Acceleration.

Authors:  Uri Galili
Journal:  Adv Wound Care (New Rochelle)       Date:  2017-03-01       Impact factor: 4.730

8.  Mixed chimerism induced without lethal conditioning prevents T cell- and anti-Gal alpha 1,3Gal-mediated graft rejection.

Authors:  H Ohdan; Y G Yang; A Shimizu; K G Swenson; M Sykes
Journal:  J Clin Invest       Date:  1999-08       Impact factor: 14.808

9.  Possible role of a cell surface carbohydrate in evolution of resistance to viral infections in old world primates.

Authors:  Idalia A Rodriguez; Raymond M Welsh
Journal:  J Virol       Date:  2013-06-05       Impact factor: 5.103

10.  High antigen levels do not preclude B-cell tolerance induction to alpha1,3-Gal via mixed chimerism.

Authors:  Fabienne Haspot; Philip D Bardwell; Guiling Zhao; Megan Sykes
Journal:  Xenotransplantation       Date:  2008 Sep-Oct       Impact factor: 3.907

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.